Susanne Nicole Weber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Susanne Nicole Weber has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Frank Lammert
Health Sciences, Hannover Medical School (MHH), Hannover, Germany
12 shared publications - Marcin Krawczyk
Department of Gastroenterology, Hepatology and Transplant Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany
9 shared publications Frank Lammert
Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany
4 shared publications- Vincent Zimmer
Department of Medicine, Knappschaftsklinik Saar, Püttlingen, Germany; Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany
3 shared publications - Agostino Di Ciaula
Internal Medicine Clinica Medica “A. Murri”, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari ‘Aldo Moro’, 70121 Bari, Italy
2 shared publications Andreas Geier
Division of Hepatology Department of Medicine II University Hospital Würzburg Würzburg Germany
2 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (8)
Metabolic Dysfunction‐Associated Steatotic Disease and Genetic Risk in Germany—An Observational Real‐World Cohort Study
Background: Metabolic dysfunction‐associated steatotic disease (MASLD) affects increasing numbers of patients worldwide. The PNPLA3 p.I148M variant represents a major genetic determinant of MASLD progression. The loss‐of‐function HSD17B13 polymorphism rs72613567 was reported in turn to be hepatoprotective. Patients: We analysed blood samples of 507 patients recruited within the Fatty Liver Assessment in Germany (FLAG) study, of whom 476 (255 males, age 56 years) were genotyped. FLAG is a multicenter real‐world MASLD cohort covering secondary and tertiary healthcare levels. The PNPLA3 p.I148M and the HSD17B13 rs72613567 polymorphisms were genotyped using allelic discrimination assays. The control cohort comprised 174 individuals. Results: The PNPLA3 p.I148M variant was prevalent among FLAG patients ( p < 0.001 for the departure from Hardy–Weinberg equilibrium) and increased the risk of developing MASLD (common OR = 2.46, p = 6.238e‐09). It was associated with increased ALT and AST, lower serum triglyceride concentrations, and independently with liver stiffness ≥ 9.1 kPa after adjustment for BMI and diabetes (OR = 2.57, p = 0.01). Carriers of the HSD17B13 rs72613567 variant had lower AST. HSD17B13 heterozygotes had lower FIB‐4 ( p = 0.028) and lower liver stiffness ( p = 0.034). Among carriers of the PNPLA3 p.148M allele, the presence of the HSD17B13 variant was associated with lower ALT ( p = 0.023) and AST ( p = 0.041); however, HSD17B13 did not abrogate the association of PNPLA3 with liver fibrosis (adjusted p = 0.013). Discussion: By analysing a real‐world MASLD cohort in Germany, we further underscore the role of the PNPLA3 variant as the central genetic trigger and modulator of MASLD. The HSD17B13 polymorphism may exert protective effects in MASLD and could attenuate some PNPLA3 ‐associated effects.
- 7 October 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (8)
Open AccessMetabolic Dysfunction‐Associated Steatotic Disease and Genetic Risk in Germany—An Observational Real‐World Cohort Study
Background: Metabolic dysfunction‐associated steatotic disease (MASLD) affects increasing numbers of patients worldwide. The PNPLA3 p.I148M variant represents a major genetic determinant of MASLD progression. The loss‐of‐function HSD17B13 polymorphism rs72613567 was reported in turn to be hepatoprotective. Patients: We analysed blood samples of 507 patients recruited within the Fatty Liver Assessment in Germany (FLAG) study, of whom 476 (255 males, age 56 years) were genotyped. FLAG is a multicenter real‐world MASLD cohort covering secondary and tertiary healthcare levels. The PNPLA3 p.I148M and the HSD17B13 rs72613567 polymorphisms were genotyped using allelic discrimination assays. The control cohort comprised 174 individuals. Results: The PNPLA3 p.I148M variant was prevalent among FLAG patients ( p < 0.001 for the departure from Hardy–Weinberg equilibrium) and increased the risk of developing MASLD (common OR = 2.46, p = 6.238e‐09). It was associated with increased ALT and AST, lower serum triglyceride concentrations, and independently with liver stiffness ≥ 9.1 kPa after adjustment for BMI and diabetes (OR = 2.57, p = 0.01). Carriers of the HSD17B13 rs72613567 variant had lower AST. HSD17B13 heterozygotes had lower FIB‐4 ( p = 0.028) and lower liver stiffness ( p = 0.034). Among carriers of the PNPLA3 p.148M allele, the presence of the HSD17B13 variant was associated with lower ALT ( p = 0.023) and AST ( p = 0.041); however, HSD17B13 did not abrogate the association of PNPLA3 with liver fibrosis (adjusted p = 0.013). Discussion: By analysing a real‐world MASLD cohort in Germany, we further underscore the role of the PNPLA3 variant as the central genetic trigger and modulator of MASLD. The HSD17B13 polymorphism may exert protective effects in MASLD and could attenuate some PNPLA3 ‐associated effects.
- 24 February 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 146, 106793
Environmental PM10 exposure and MASLD: Challenges in translating gene–environment interactions into routine clinical care. Author's reply
- 24 February 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 146, 106793
Environmental PM10 exposure and MASLD: Challenges in translating gene–environment interactions into routine clinical care. Author's reply
- Open Access
- 10 May 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (8) , 101450
PNPLA3 I148M variant links to adverse metabolic traits in MASLD during fasting and feeding
- 10 May 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (8) , 101450
Open AccessPNPLA3 I148M variant links to adverse metabolic traits in MASLD during fasting and feeding
- Open Access
- 7 May 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (4) , 766-779
Intestinal biomarkers, microbiota composition, and genetic predisposition to inflammatory bowel disease as predictors of Parkinson's disease manifestation
Background: Parkinson's disease (PD) is often accompanied by gastrointestinal symptoms. While elevated inflammatory biomarkers have been reported in PD patients compared to controls, the role of intestinal dysmotility and inflammation in disease manifestation is not fully understood. Objective: This study sought to determine if fecal biomarkers and genetic predisposition to intestinal inflammation could help identify PD subtypes for future targeted therapies. Methods: The association of disease activity, assessed through United Parkinson's disease Rating Scale (UPDRS) and Non-Motor Symptoms Questionnaire (NMSQ), with constipation severity, fecal calprotectin and six short-chain fatty acid (SCFA) levels, polygenic risk scores (PRS) for inflammatory bowel disease (IBD) and PD, and microbiota diversity were investigated in 95 participants with established PD using regression analyses. Unsupervised k-means clustering was applied to stratify PD patients based on inflammatory biomarkers. Results: Having constipation was linked to worse mentation (UPDRSI, adj. p = 0.03) and more limited daily living activities (UPDRSII, adj. p = 0.03), with symptom severity linearly associated with higher disease activity (UPDRSI, adj. p = 0.002; NMSQ-total, adj. p = 0.02). Fecal calprotectin was elevated in those with constipation ( p = 0.02) and associated with longer disease duration irrespective of the age (adj. p = 0.02). Cluster analysis demonstrated that PD patients with a higher non-motor symptom UPDRSII score were more likely to have more severe constipation, lower fecal SCFA levels, lower bacterial diversity, and higher PRS-CD and PRS-IBD. Conclusions: Gut dysmotility, along with pro-inflammatory intestinal profiles, and greater genetic predisposition to IBD were observed in PD patients with worse non-motor symptoms. Monitoring intestinal biomarkers may help identify PD patients for targeted interventions.
- 7 May 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (4) , 766-779
Open AccessIntestinal biomarkers, microbiota composition, and genetic predisposition to inflammatory bowel disease as predictors of Parkinson's disease manifestation
Background: Parkinson's disease (PD) is often accompanied by gastrointestinal symptoms. While elevated inflammatory biomarkers have been reported in PD patients compared to controls, the role of intestinal dysmotility and inflammation in disease manifestation is not fully understood. Objective: This study sought to determine if fecal biomarkers and genetic predisposition to intestinal inflammation could help identify PD subtypes for future targeted therapies. Methods: The association of disease activity, assessed through United Parkinson's disease Rating Scale (UPDRS) and Non-Motor Symptoms Questionnaire (NMSQ), with constipation severity, fecal calprotectin and six short-chain fatty acid (SCFA) levels, polygenic risk scores (PRS) for inflammatory bowel disease (IBD) and PD, and microbiota diversity were investigated in 95 participants with established PD using regression analyses. Unsupervised k-means clustering was applied to stratify PD patients based on inflammatory biomarkers. Results: Having constipation was linked to worse mentation (UPDRSI, adj. p = 0.03) and more limited daily living activities (UPDRSII, adj. p = 0.03), with symptom severity linearly associated with higher disease activity (UPDRSI, adj. p = 0.002; NMSQ-total, adj. p = 0.02). Fecal calprotectin was elevated in those with constipation ( p = 0.02) and associated with longer disease duration irrespective of the age (adj. p = 0.02). Cluster analysis demonstrated that PD patients with a higher non-motor symptom UPDRSII score were more likely to have more severe constipation, lower fecal SCFA levels, lower bacterial diversity, and higher PRS-CD and PRS-IBD. Conclusions: Gut dysmotility, along with pro-inflammatory intestinal profiles, and greater genetic predisposition to IBD were observed in PD patients with worse non-motor symptoms. Monitoring intestinal biomarkers may help identify PD patients for targeted interventions.
- 28 November 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 80 (6) , e256-e257
ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort
- 28 November 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 80 (6) , e256-e257
ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort
- Open Access
Altered Expression of Antimicrobial Peptides in the Upper Gastrointestinal Tract of Patients with Diabetes Mellitus
Antimicrobial peptides (AMP) are essential components of innate immunity with a broad range of antimicrobial activities against bacteria, viruses, and fungi. The aim of this study was to investigate AMP expression in the upper gastrointestinal tract in normal and pathological metabolic states in humans. Furthermore, we examined the correlation between vitamin D levels and AMP expression in the same cohort. Serum concentrations of 25-hydroxyvitamin D3 were measured, and mRNA expression of β-defensins HBD-1, -2, -3, -4, α-defensins HD-5 and -6 and cathelicidin in the upper gastrointestinal tract epithelia were determined by quantitative RT-PCR in 31 individuals (10 with type 2 diabetes, 10 with insulin resistance, and 11 healthy controls). The majority of the cohort showed low vitamin D concentrations, which were negatively correlated with mRNA expression levels of HBD-3 in corpus mucosa. HBD-1 and HBD-3 mRNA were expressed in corpus mucosa, with the former significantly decreased in patients with diabetes. Hence, we conclude that type 2 diabetes is associated with reduced AMP expression in the upper gastrointestinal tract, which might contribute towards epithelial barrier dysfunction and increased bacterial translocation in these patients.
Open AccessAltered Expression of Antimicrobial Peptides in the Upper Gastrointestinal Tract of Patients with Diabetes Mellitus
Antimicrobial peptides (AMP) are essential components of innate immunity with a broad range of antimicrobial activities against bacteria, viruses, and fungi. The aim of this study was to investigate AMP expression in the upper gastrointestinal tract in normal and pathological metabolic states in humans. Furthermore, we examined the correlation between vitamin D levels and AMP expression in the same cohort. Serum concentrations of 25-hydroxyvitamin D3 were measured, and mRNA expression of β-defensins HBD-1, -2, -3, -4, α-defensins HD-5 and -6 and cathelicidin in the upper gastrointestinal tract epithelia were determined by quantitative RT-PCR in 31 individuals (10 with type 2 diabetes, 10 with insulin resistance, and 11 healthy controls). The majority of the cohort showed low vitamin D concentrations, which were negatively correlated with mRNA expression levels of HBD-3 in corpus mucosa. HBD-1 and HBD-3 mRNA were expressed in corpus mucosa, with the former significantly decreased in patients with diabetes. Hence, we conclude that type 2 diabetes is associated with reduced AMP expression in the upper gastrointestinal tract, which might contribute towards epithelial barrier dysfunction and increased bacterial translocation in these patients.
- Open Access
- 13 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15825
MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery
The severity of hepatic steatosis is modulated by genetic variants, such as patatin-like phospholipase domain containing 3 (PNPLA3) rs738409, transmembrane 6 superfamily member 2 (TM6SF2) rs58542926, and membrane-bound O-acyltransferase domain containing 7 (MBOAT7) rs641738. Recently, mitochondrial amidoxime reducing component 1 (MTARC1) rs2642438 and hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) rs72613567 polymorphisms were shown to have protective effects on liver diseases. Here, we evaluate these variants in patients undergoing bariatric surgery. A total of 165 patients who underwent laparoscopic sleeve gastrectomy and intraoperative liver biopsies and 314 controls were prospectively recruited. Genotyping was performed using TaqMan assays. Overall, 70.3% of operated patients presented with hepatic steatosis. NASH (non-alcoholic steatohepatitis) was detected in 28.5% of patients; none had cirrhosis. The increment of liver fibrosis stage was associated with decreasing frequency of the MTARC1 minor allele (p = 0.03). In multivariate analysis MTARC1 was an independent protective factor against fibrosis ≥ 1b (OR = 0.52, p = 0.03) and ≥ 1c (OR = 0.51, p = 0.04). The PNPLA3 risk allele was associated with increased hepatic steatosis, fibrosis, and NASH (OR = 2.22, p = 0.04). The HSD17B13 polymorphism was protective against liver injury as reflected by lower AST (p = 0.04) and ALT (p = 0.03) activities. The TM6SF2 polymorphism was associated with increased ALT (p = 0.04). In conclusion, hepatic steatosis is common among patients scheduled for bariatric surgery, but the MTARC1 and HSD17B13 polymorphisms lower liver injury in these individuals.
- 13 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15825
Open AccessMTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery
The severity of hepatic steatosis is modulated by genetic variants, such as patatin-like phospholipase domain containing 3 (PNPLA3) rs738409, transmembrane 6 superfamily member 2 (TM6SF2) rs58542926, and membrane-bound O-acyltransferase domain containing 7 (MBOAT7) rs641738. Recently, mitochondrial amidoxime reducing component 1 (MTARC1) rs2642438 and hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) rs72613567 polymorphisms were shown to have protective effects on liver diseases. Here, we evaluate these variants in patients undergoing bariatric surgery. A total of 165 patients who underwent laparoscopic sleeve gastrectomy and intraoperative liver biopsies and 314 controls were prospectively recruited. Genotyping was performed using TaqMan assays. Overall, 70.3% of operated patients presented with hepatic steatosis. NASH (non-alcoholic steatohepatitis) was detected in 28.5% of patients; none had cirrhosis. The increment of liver fibrosis stage was associated with decreasing frequency of the MTARC1 minor allele (p = 0.03). In multivariate analysis MTARC1 was an independent protective factor against fibrosis ≥ 1b (OR = 0.52, p = 0.03) and ≥ 1c (OR = 0.51, p = 0.04). The PNPLA3 risk allele was associated with increased hepatic steatosis, fibrosis, and NASH (OR = 2.22, p = 0.04). The HSD17B13 polymorphism was protective against liver injury as reflected by lower AST (p = 0.04) and ALT (p = 0.03) activities. The TM6SF2 polymorphism was associated with increased ALT (p = 0.04). In conclusion, hepatic steatosis is common among patients scheduled for bariatric surgery, but the MTARC1 and HSD17B13 polymorphisms lower liver injury in these individuals.
- 6 September 2022
- Published by Springer Nature
- p. 75-92
Pathophysiologie: Genetik
- 1 March 2022
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 46 (3) , 101800
Intrahepatic cholestasis of pregnancy in conjunction with a frameshift deletion in FGFR4
- 1 March 2022
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 46 (3) , 101800
Intrahepatic cholestasis of pregnancy in conjunction with a frameshift deletion in FGFR4